Cabaletta Bio and WuXi ATU expand GMP manufacturing for CABA-201; dedicated suite for commercial readiness

Cabaletta Bio, Inc.

WuXi ATU to provide GMP manufacturing for CABA-201, including commercial readiness, under expanded work orders.
Dedicated suite added for CABA-201 and MuSK-CAART programs; initial 18-month term with two 18-month extensions at Cabaletta's option.
Termination fee revised to $1.08M if both programs terminated; Cabaletta can terminate with 6 months' notice.
Expansion supports planned parallel Phase 1/2 trials in SLE and myositis, plus potential late-stage trials.
Cabaletta cites capital-efficient manufacturing strategy and prior successful collaboration with WuXi ATU.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.